AstraZeneca PLC (AZN)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
AZN
AstraZeneca PLC
$156.90
-0.51%
HEALTHCARE · Cap: $243.34B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$1.94
-3.00%
HEALTHCARE · Cap: $144.85M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 311005% more annual revenue ($61.37B vs $19.73M). AZN leads profitability with a 17.0% profit margin vs 6.0%. ZJYL trades at a lower P/E of 9.7x. AZN earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy63
out of 100
Grade: C+
ZJYL
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.8%
Fair Value
$195.54
Current Price
$156.90
$38.64 discount
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.7% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.18 suggests the stock is reasonably priced for its growth.
Bull Case : ZJYL
The strongest argument for ZJYL centers on P/E Ratio, Price/Book.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.
ZJYL carries more volatility with a beta of 7.33 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (63/100 vs 19/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?